申请人:Lycera Corporation
公开号:US20170267643A1
公开(公告)日:2017-09-21
The invention provides pyrazolyl guanidine compounds that inhibit F
1
F
o
-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.